Clinical trial
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
NCT00271505 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00271505 |
|---|---|
| Title | Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer |
| Official title | A Phase II Evaluation of Avastin in Combination With Docetaxel and Carboplatin as Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab (Avastin), Carboplatin, Docetaxel |
| Enrollment | 43 |
| Start date | Dec 5, 2005 |
| Primary completion | Jul 27, 2017 |
| Completion | Jul 27, 2017 |
| First posted | Jan 2, 2006 |
| Last update posted | May 11, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: